Gilead Sciences, Inc. (GIS.DE) XETRA

110.30

-2.18(-1.94%)

Updated at June 02 05:35PM

Currency In EUR

Key Executives

Name	Title	Pay	Year Born
Daniel O'Day	Chairman & Chief Executive Officer	7.47M	1965
Andrew D. Dickinson	Executive VP & CFO	2.7M	1970
Johanna Mercier	Chief Commercial & Corporate Affairs Officer	2.95M	1970
Dietmar Berger	Chief Medical Officer	5.09M	1969
Flavius Martin	Executive Vice President of Research	0	N/A
Linda Slanec Higgins	Senior Vice President of Research, Innovation & Portfolio	0	1962
Stacey Y. Ma	Executive VP of Pharmaceutical Development & Manufacturing	0	1971
Bernard Fine	Vice President of Oncology & Franchise Head of Early Development	0	N/A
Erin Burkhart	Senior VP, Controller & Chief Accounting Officer	0	1979
Jacquie Ross	Senior Vice President of Treasury and Investor Relations	0	N/A
Janet Dorling	Senior Vice President of Intercontinental Region & Global Patient Solutions	0	1975
Jyoti K. Mehra	Executive Vice President of Human Resources	0	1977
Keeley Wettan	Executive VP, General Counsel of Legal & Compliance and Secretary	0	1975

Name

Title

Pay

Year Born

Daniel O'Day

Chairman & Chief Executive Officer

7.47M

1965

Andrew D. Dickinson

Executive VP & CFO

2.7M

1970

Johanna Mercier

Chief Commercial & Corporate Affairs Officer

2.95M

1970

Dietmar Berger

Chief Medical Officer

5.09M

1969

Flavius Martin

Executive Vice President of Research

N/A

Linda Slanec Higgins

Senior Vice President of Research, Innovation & Portfolio

1962

Stacey Y. Ma

Executive VP of Pharmaceutical Development & Manufacturing

1971

Bernard Fine

Vice President of Oncology & Franchise Head of Early Development

N/A

Erin Burkhart

Senior VP, Controller & Chief Accounting Officer

1979

Jacquie Ross

Senior Vice President of Treasury and Investor Relations

N/A

Janet Dorling

Senior Vice President of Intercontinental Region & Global Patient Solutions

1975

Jyoti K. Mehra

Executive Vice President of Human Resources

1977

Keeley Wettan

Executive VP, General Counsel of Legal & Compliance and Secretary

1975

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.